Jonathan Sheena sold $7.0M of NTRA
director, other at Natera, Inc.. 18,064 shares at an average of $388.01, traded Sep 23, 2026, filed Sep 25, 2026.
Score components
- +15RoleDirector
- +25Trade size$7.0M at market
- +20Share of holdings soldSold 100% of holdings
- +15Cluster4 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001646649-26-000033, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 23, 2026 | SOpen-market sale Common Stockindirect: By Caraluna 1 Trust10b5-1 | -400 | $385.10 | $154k | 17,632 | 16 d ago |
| Sep 23, 2026 | SOpen-market sale Common Stockindirect: By Caraluna 1 Trust10b5-1 | -2,175 | $386.71 | $841k | 15,457 | 16 d ago |
| Sep 23, 2026 | SOpen-market sale Common Stockindirect: By Caraluna 1 Trust10b5-1 | -2,734 | $387.65 | $1.1M | 12,723 | 16 d ago |
| Sep 23, 2026 | SOpen-market sale Common Stockindirect: By Caraluna 1 Trust10b5-1 | -1,293 | $388.71 | $503k | 11,430 | 16 d ago |
| Sep 23, 2026 | SOpen-market sale Common Stockindirect: By Caraluna 1 Trust10b5-1 | -2,320 | $389.69 | $904k | 9,110 | 16 d ago |
| Sep 23, 2026 | SOpen-market sale Common Stockindirect: By Caraluna 1 Trust10b5-1 | -110 | $390.42 | $43k | 9,000 | 16 d ago |
| Sep 23, 2026 | SOpen-market sale Common Stockindirect: By Caraluna 2 Trust10b5-1 | -390 | $385.29 | $150k | 17,642 | 16 d ago |
| Sep 23, 2026 | SOpen-market sale Common Stockindirect: By Caraluna 2 Trust10b5-1 | -2,300 | $386.64 | $889k | 15,342 | 16 d ago |
| Sep 23, 2026 | SOpen-market sale Common Stockindirect: By Caraluna 2 Trust10b5-1 | -2,846 | $387.74 | $1.1M | 12,496 | 16 d ago |
| Sep 23, 2026 | SOpen-market sale Common Stockindirect: By Caraluna 2 Trust10b5-1 | -1,341 | $388.76 | $521k | 11,155 | 16 d ago |
| Sep 23, 2026 | SOpen-market sale Common Stockindirect: By Caraluna 2 Trust10b5-1 | -1,935 | $389.71 | $754k | 9,220 | 16 d ago |
| Sep 23, 2026 | SOpen-market sale Common Stockindirect: By Caraluna 2 Trust10b5-1 | -220 | $390.53 | $86k | 9,000 | 16 d ago |
Related signals
Other insiders at Natera, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 38Weak | Natera, Inc. | Steven Leonard Chapman CEO AND PRESIDENT | $526k 1,273 shares | -1% | |
| 40Moderate | Natera, Inc. | Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS | $1.2M 3,000 shares | -3% | |
| 35Weak | Natera, Inc. | Jonathan Sheena director, other | $3.2M 9,150 shares | -4% | |
| 40Moderate | Natera, Inc. | Matthew Rabinowitz EXECUTIVE CHAIRMAN | $35M 102,000 shares | -5% | |
| 40Moderate | Natera, Inc. | Matthew Rabinowitz EXECUTIVE CHAIRMAN | $16M 50,000 shares | -2% | |
| 39Weak | Natera, Inc. | Steven Leonard Chapman CEO AND PRESIDENT | $545k 1,698 shares | -2% | |
| 45Moderate | Natera, Inc. | Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS | $5.9M 18,160 shares | -14% | |
| 27Weak | Natera, Inc. | Michael Burkes Brophy CHIEF FINANCIAL OFFICER | $116k 792 shares | -1% | |
| 45Moderate | Natera, Inc. | Steven Leonard Chapman CEO AND PRESIDENT | $979k 6,702 shares | -3% | |
| 25Weak | Natera, Inc. | John Fesko PRESIDENT, CHIEF BUS. OFFICER | $116k 795 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.